Scorpion Therapeutics
Oct 26, 2020 · Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα And EGFR Exon 20, Two Established Cancer Drivers With Broad Therapeutic Applicability
About - Scorpion Therapeutics
At Scorpion Therapeutics, we are expanding the reach of precision medicine to more people with untreatable or treatment-resistant cancer.
Pipeline – Scorpion Therapeutics
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small …
News – Scorpion Therapeutics
Oct 13, 2023 · Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other …
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at …
Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally …
Scorpion Therapeutics Enters Agreement With Astrazeneca To …
– January 13, 2022 – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company pioneering Precision Oncology 2.0, today announced a collaboration with …
Scorpion Therapeutics Presents Initial Clinical Data from Its Phase …
Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally …
Science – Scorpion Therapeutics
These technologies allow our scientists at Scorpion to connect the disruption in individual genes needed for cancer cell survival with the underlying genetic and proteomic characteristics of the …
Careers – Scorpion Therapeutics
A lot of companies try to advertise cross-collaboration. At Scorpion, it’s not only true, but better than I could have imagined.
Scorpion Therapeutics Announces Formation of World-Class …
BOSTON, Mass. – November 7, 2022 – Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its …